The AHA today urged the Drug Enforcement Administration to explicitly consider drug shortages when setting and adjusting aggregate production quotas, citing concern that the agency’s proposal to reduce 2020 production quotas for five opioid controlled substances would exacerbate shortages of injectable opioid medications. “Beyond the negative impact on patient care, inadequate supplies of these drugs also creates burdensome and potentially dangerous workarounds for health care staff who must use alternative, often suboptimal products,” AHA wrote. Among other actions, AHA continued to recommend that DEA routinely consult with the Food and Drug Administration when establishing and adjusting quotas. “Obtaining [national drug] shortage data from the FDA will help to ensure that the DEA’s annual production quotas are set to provide adequate supplies for the United States’ legitimate needs,” the association said.

Related News Articles

Headline
Achieving operational and survey readiness on day one is an issue that many health care facilities professionals continue to grapple with, according to…
Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
Health delivery organizations are encouraged to apply by 1 p.m. ET May 6 for the AHA’s 2026 Foster G. McGaw Prize, honoring organizations that demonstrate…
Headline
Hospitals and health systems are urged to nominate candidates as soon as possible for the AHA Next Generation Leaders Fellowship so they can apply by the March…
Headline
The Hospital Capacity Management Consortium, a professional membership group for hospital capacity management leaders, is now part of the AHA. The HCMC was…
Headline
Ian Morrison, a highly regarded author, consultant and futurist, died last week. He specialized in long-term forecasting and planning with a particular…